Cholinergic Urticaria Clinical Trial
Official title:
An Open Label, Phase 1 Single Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add on Therapy in Patients With Cold Contact Urticaria, Symptomatic Dermographism and Cholinergic Urticaria
This is a study to determine the safety of CDX-0159 in patients with Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria.
This study is an open label Phase 1 study evaluating the safety, pharmacokinetics, and pharmacodynamics of a single dose of CDX-0159 in patients with Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria who remain symptomatic despite treatment with antihistamines. Twenty patients with Cold Contact Urticaria, ten patients with Symptomatic Dermographism, and ten patients with Cholinergic Urticaria will be enrolled in four separate cohorts for a total of 40 patients. Prospective patients will be screened with tests in clinic as well as daily at home diaries for 2 weeks prior to enrollment. CDX-0159 will be administered intravenously on Day 1. Post-treatment, patients will be followed for 12 weeks with an optional longer term follow up period. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04853992 -
Trial to Assess the Efficacy and Safety of LEO 152020 in Adult Patients With Cholinergic Urticaria
|
Phase 2 | |
| Completed |
NCT02012387 -
Efficacy Study of Omalizumab in Cholinergic Urticaria
|
Phase 2 | |
| Recruiting |
NCT06201780 -
Assessment of Serum Levels of Janus Kinase 1 and 2 in Patients With Cholinergic Urticaria
|
N/A | |
| Completed |
NCT03749148 -
Cholinergic Urticaria - Efficacy of Dupilumab
|
Phase 2 | |
| Terminated |
NCT04513548 -
Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic Urticaria
|
Phase 1 |